Scientists test bold new combo to outsmart aggressive breast cancer
NCT ID NCT07471815
Summary
This study is testing a new three-drug combination for a hard-to-treat type of breast cancer called triple-negative. It combines an immunotherapy drug (camrelizumab), a common bone-strengthening drug (risedronate), and standard chemotherapy. The goal is to see if this combo can work better than current treatments by attacking the cancer in two ways at once and overcoming treatment resistance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 158100, China
Conditions
Explore the condition pages connected to this study.